Skip to content
Tevogen

Tevogen

  • Technology
    • Innovative Science
    • COVID-19
    • Publications
  • Pipeline
    • Clinical Trials
  • Investors
    • Executive Summary
    • Corporate Overview
  • Strategic Alliances
    • Executive Summary
    • Corporate Overview
  • Leadership
  • Newsroom
    • Highlights
    • Latest News
    • New Corporate Office
    • Future R&D Facility
    • Social Media
  • Careers
  • Contact Us

Publications

Publications

Loss of an Immunodominant HLA-A *01:01 Restricted Epitope for CD8+ Cytotoxic T Lymphocytes (CTLs) in the Delta Variant of COVID-19: An Example of Immunologic Escape and Implications for Immunologic Treatment

November 23, 2021


TVGN-489: A novel approach for the production of SARS-CoV-2-specific cytotoxic T lymphocytes to treat COVID-19

May 1, 2021



New Jersey, USA

  • Twitter
  • LinkedIn
  • Tevogen YouTube

Contact Us

© 2023 Tevogen Bio. All Rights Reserved.

Tevogen,